Skip to content
Medical Health Aged Care, Research Development

Global experts unite to redefine diagnostic criteria for vascular dementia

Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney 2 mins read

An international team of clinicians and researchers, led by the Centre for Healthy Brain Ageing’s Professor Perminder Sachdev and Dr Adam Bentvelzen, has today unveiled new diagnostic criteria for vascular cognitive impairment and dementia (VCID) – a common but less well-known cause of dementia.

The criteria, published in JAMA Neurology, aim to bring clarity and consistency to the diagnosis of VCID, which includes vascular dementia and milder forms of vascular-related cognitive decline.

As part of an international consortium involving experts from more than 20 countries and backed by the World Stroke Organization, the new VASCOG-2-WSO Criteria is an update of the original VASCOG criteria released in 2014. They incorporate the latest scientific developments in neuroimaging and biomarkers and offer detailed, practical guidance to support clinical and research diagnosis globally.

VCID, which results from damage to the brain’s blood vessels, is the second most common cause of dementia after Alzheimer’s disease. Yet, despite its high prevalence and potential for prevention, progress has been hampered by a lack of standardised diagnostic tools.

“This is a major step forward,” said Prof. Perminder Sachdev, lead author and Co-Director of UNSW’s Centre for Healthy Brain Ageing (CHeBA).

“With these criteria, we now have an international standard that will help clinicians more confidently diagnose vascular contributions to cognitive impairment and dementia - and support more targeted, collaborative research.”

Developed through a rigorous three-round Delphi consensus process, the criteria reflect input from over 50 world-leading clinicians and researchers in ageing, dementia and stroke. Notably, they introduce new categories such as preclinical’ or ‘at-risk’ VCID, helping identify people who may benefit from early intervention before symptoms emerge.

“Vascular contributions to cognitive decline are widespread but under-recognised,” said Dr Adam Bentvelzen, Study Coordinator and Senior Research Associate. “This work will be crucial for more accurate diagnosis, better global research collaboration, and ultimately for developing effective interventions.”

The new VASCOG-2-WSO criteria align with recent international dementia guidelines and are already being endorsed as a global benchmark for the field. The authors hope they will be adopted in clinical settings, research studies, and future treatment trials focused on preventing and managing vascular brain injury.


Contact details:

Heidi Douglass

[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 09/12/2025
  • 11:08
Australian Society of Anaesthetists

Getting to the facts on specialist fees and clearing up the confusion, from those that create it.

Anaesthetists in Australia provide over 2.6 million episodes of care each year, delivering individualised, high-quality, and safety-driven services that enable patients to undergo surgery,…

  • Contains:
  • Medical Health Aged Care
  • 09/12/2025
  • 05:30
Centre for Eye Research Australia

Australian scientists reveal new genetic risk for severe macular degeneration

Researchers and a person living with macular degeneration are available for interview in East Melbourne today. Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of age-related macular degeneration (AMD). A new study, published today inNature Communications, reveals the specific genetic factors linked to the presence of reticular pseudodrusen - deposits which drive vision loss and are found on the retina of up to 60 per cent of people with advanced AMD. The research, led by the Centre for Eye Research Australia, WEHI and the University of Melbourne, offers a…

  • Medical Health Aged Care
  • 09/12/2025
  • 01:11
SoluPet Inc.

SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia

Partnership with CHC in Taiwan will pilot SoluPet’s flagship Neuronal Defense™ formulation through CHC’s veterinary and consumer-health ecosystem TORONTO–BUSINESS WIRE– SoluPet,the data and science-driven…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.